Founded in 2015 and located in Zhongguancun Science and Technology Park, TargetingOne is a national high-tech enterprise and Beijing "Specialized, special and new" enterprise, focusing on independent innovation of molecular diagnostic technology and the translation of major disease applications, with a high-level research and development team in the field of instruments, chips, materials, reagents and software. The company has been developing rapidly, applying for more than 180 domestic and foreign patents, granting more than 100 patents, continuously publishing academic papers in authoritative journals and undertaking national research funds. Based on its own intellectual property rights, the digital PCR system developed by the company has won the first NMPA Class III medical device registration certificate for SARS-Cov-2 detection reagents based on digital PCR technology, and won the Gold Award of China In Vitro Diagnostic Excellent Innovation Product for two consecutive years and the overall champion of Zhongguancun International Frontier Science and Technology Innovation Competition. We are committed to be a leading life science and molecular diagnostic company, serving life science, precision medicine, drug development and health management by developing multi-indicator, high-throughput, automated, anti-contamination and lowcost molecular diagnostic technologies.
